{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T09:01:09Z","timestamp":1777194069330,"version":"3.51.4"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,5,13]],"date-time":"2019-05-13T00:00:00Z","timestamp":1557705600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,13]],"date-time":"2019-05-13T00:00:00Z","timestamp":1557705600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s00702-019-02012-0","type":"journal-article","created":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T02:10:39Z","timestamp":1557799839000},"page":"925-932","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Dyskinesia in multiple system atrophy and progressive supranuclear palsy"],"prefix":"10.1007","volume":"126","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8574-3297","authenticated-orcid":false,"given":"Wolfgang H.","family":"Jost","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Lingor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"T\u00f6nges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten","family":"Buhmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Kassubek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anette","family":"Schrag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,13]]},"reference":[{"key":"2012_CR1","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1212\/WNL.44.7.1325","volume":"44","author":"A Antonini","year":"1994","unstructured":"Antonini A, Schwarz J, Oertel WH, Beer HF, Madeja UD, Leenders KL (1994) [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson\u2019s disease: influence of l-dopa and lisuride therapy on striatal dopamine D2-receptors. Neurology 44:1325\u20131329","journal-title":"Neurology"},{"key":"2012_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/mds.870120107","volume":"12","author":"A Antonini","year":"1997","unstructured":"Antonini A, Schwarz J, Oertel WH, Pogarell O, Leenders KL (1997) Long-term changes of striatal dopamine D2 receptors in patients with Parkinson\u2019s disease: a study with positron emission tomography and [11C]raclopride. Mov Disord 12:33\u201338","journal-title":"Mov Disord"},{"key":"2012_CR3","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1002\/mds.27450","volume":"33","author":"A Batla","year":"2018","unstructured":"Batla A, De Pablo-Fernandez E, Erro R, Reich M, Calandra-Buonaura G, Barbosa P, Balint B, Ling H, Islam S, Cortelli P, Volkmann J, Quinn N, Holton JL, Warner TT, Bhatia KP (2018) Young-onset multiple system atrophy: clinical and pathological features. Mov Disord 33:1099\u20131107","journal-title":"Mov Disord"},{"key":"2012_CR4","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/mds.10190","volume":"17","author":"J Berciano","year":"2002","unstructured":"Berciano J, Valldeoriola F, Ferrer I, Rumi\u00e0 J, Pascual J, Mar\u00edn C, Rey MJ, Tolosa E (2002) Presynaptic parkinsonism in multiple system atrophy mimicking Parkinson\u2019s disease: a clinicopathological case study. Mov Disord 17:812\u2013816","journal-title":"Mov Disord"},{"key":"2012_CR5","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1002\/mds.10211","volume":"17","author":"S Birdi","year":"2002","unstructured":"Birdi S, Rajput AH, Fenton M, Donat JR, Rozdilsky B, Robinson C, Macaulay R, George D (2002) Progressive supranuclear palsy diagnosis and confounding features: report on 16 autopsied cases. Mov Disord 17:1255\u20131264","journal-title":"Mov Disord"},{"key":"2012_CR6","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1002\/mds.870130507","volume":"13","author":"PJ Blanchet","year":"1998","unstructured":"Blanchet PJ, Konitsiotis S, Chase TN (1998) Amantadine reduces levodopa-induced dyskinesias in Parkinsonian monkeys. Mov Disord 13:798\u2013802","journal-title":"Mov Disord"},{"key":"2012_CR7","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1136\/jnnp.72.3.300","volume":"72","author":"S Boesch","year":"2002","unstructured":"Boesch S, Wenning GK, Ransmayr G, Poewe W (2002) Dystonia in multiple system atrophy. J Neurol Neurosurg Psych 72:300\u2013303","journal-title":"J Neurol Neurosurg Psych"},{"key":"2012_CR8","first-page":"43","volume":"22","author":"DF Cai","year":"2002","unstructured":"Cai DF, Chen XQ, Gao Y (2002) Effect of bushen yanggan recipe on nigrostriatal function in parkinsonian model rats after long-term levodopa treatment. Zhongguo Zhong Xi Yi Jie He Za Zhi 22:43\u201346","journal-title":"Zhongguo Zhong Xi Yi Jie He Za Zhi"},{"key":"2012_CR9","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/S1474-4422(10)70218-0","volume":"9","author":"P Calabresi","year":"2010","unstructured":"Calabresi P, Di Filippo M, Ghiglieri V, Tambasco N, Picconi B (2010) Levodopa-induced dyskinesias in patients with Parkinson\u2019s disease: filling the bench-to-bedside gap. Lancet Neurol 9:1106\u20131117","journal-title":"Lancet Neurol"},{"key":"2012_CR10","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1093\/brain\/awu195","volume":"137","author":"R Cilia","year":"2014","unstructured":"Cilia R, Akpalu A, Sarfo FS, Cham M, Amboni M, Cereda E, Fabbri M, Adjei P, Akassi J, Bonetti A, Pezzoli G (2014) The modern pre-levodopa era of Parkinson\u2019s disease: insights into motor complications from sub-Saharan Africa. Brain 137:2731\u20132742","journal-title":"Brain"},{"key":"2012_CR11","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1002\/mds.21578","volume":"22","author":"R Constantinescu","year":"2007","unstructured":"Constantinescu R, Richard I, Kurlan R (2007) Levodopa responsiveness in disorders with Parkinsonism: a review of the literature. Mov Disord 22:2141\u20132148","journal-title":"Mov Disord"},{"key":"2012_CR12","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/0091-3057(94)90123-6","volume":"47","author":"GE Drucker","year":"1994","unstructured":"Drucker GE, Ritzmann RF, Wichlinski LJ, Engh K, Gordon JH, Fields JZ (1994) Prevention and reversal of dopamine receptor supersensitivity by cyclo(leucyl-glycyl) (CLG): biphasic dose-response curves. Pharmacol Biochem Behav 47:141\u2013145","journal-title":"Pharmacol Biochem Behav"},{"key":"2012_CR13","first-page":"342","volume":"57","author":"AW Dunah","year":"2000","unstructured":"Dunah AW, Wang Y, Yasuda RP, Kameyama K, Huganir RL, Wolfe BB, Standaert DG (2000) Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-D-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson\u2019s disease. Mol Pharmacol 57:342\u2013352","journal-title":"Mol Pharmacol"},{"key":"2012_CR14","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/ana.25364","volume":"84","author":"AJ Espay","year":"2018","unstructured":"Espay AJ, Morgante F, Merola A, Fasano A, Marsili L, Fox SH, Bezard E, Picconi B, Calabresi P, Lang AE (2018) Levodopa-induced dyskinesia in Parkinson disease: current and evolving concepts. Ann Neurol 84:797\u2013811","journal-title":"Ann Neurol"},{"key":"2012_CR16","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1001\/archneur.56.5.529","volume":"56","author":"S Fahn","year":"1999","unstructured":"Fahn S (1999) Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA. Arch Neurol 56:529\u2013535","journal-title":"Earlier vs Later L-DOPA. Arch Neurol"},{"key":"2012_CR17","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1093\/brain\/awx118","volume":"140","author":"SM Fereshtehnejad","year":"2017","unstructured":"Fereshtehnejad SM, Zeighami Y, Dagher A, Postuma RB (2017) Clinical criteria for subtyping Parkinson\u2019s disease: biomarkers and longitudinal progression. Brain 140:1959\u20131976","journal-title":"Brain"},{"key":"2012_CR18","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/nan.12400","volume":"43","author":"MP Frosch","year":"2017","unstructured":"Frosch MP (2017) Tau aggregates: where, when, why and what consequences? Neuropathol Appl Neurobiol 43:371\u2013372","journal-title":"Neuropathol Appl Neurobiol"},{"key":"2012_CR19","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S0014-2999(99)00569-5","volume":"382","author":"M Geurts","year":"1999","unstructured":"Geurts M, Hermans E, Maloteaux JM (1999) Enhanced striatal dopamine D(2) receptor-induced [35S]GTPgammaS binding after haloperidol treatment. Eur J Pharmacol 382:119\u2013127","journal-title":"Eur J Pharmacol"},{"key":"2012_CR20","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1212\/WNL.38.9.1402","volume":"38","author":"WR Gibb","year":"1988","unstructured":"Gibb WR, Lees AJ (1988) A comparison of clinical and pathological features of young- and old-onset Parkinson\u2019s disease. Neurology 38:1402\u20131406","journal-title":"Neurology"},{"key":"2012_CR21","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1212\/01.wnl.0000324625.00404.15","volume":"71","author":"S Gilman","year":"2008","unstructured":"Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, Wood NW, Colosimo C, Durr A, Fowler CJ, Kaufmann H, Klockgether T, Lees A, Poewe W, Quinn N, Revesz T, Robertson D, Sandroni P, Seppi K, Vidailhet M (2008) Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71:670\u2013676","journal-title":"Neurology"},{"key":"2012_CR22","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/(SICI)1098-2396(199902)31:2<154::AID-SYN9>3.0.CO;2-K","volume":"31","author":"N Ginovart","year":"1999","unstructured":"Ginovart N, Farde L, Halldin C, Swahn CG (1999) Changes in striatal D2-receptor density following chronic treatment with amphetamine as assessed with PET in nonhuman primates. Synapse 31:154\u2013162","journal-title":"Synapse"},{"key":"2012_CR23","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/mds.26987","volume":"32","author":"GU H\u00f6glinger","year":"2017","unstructured":"H\u00f6glinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, Mollenhauer B, Muller U, Nilsson C, Whitwell JL, Arzberger T, Englund E, Gelpi E, Giese A, Irwin DJ, Meissner WG, Pantelyat A, Rajput A, van Swieten JC, Troakes C, Antonini A, Bhatia KP, Bordelon Y, Compta Y, Corvol JC, Colosimo C, Dickson DW, Dodel R, Ferguson L, Grossman M, Kassubek J, Krismer F, Levin J, Lorenzl S, Morris HR, Nestor P, Oertel WH, Poewe W, Rabinovici G, Rowe JB, Schellenberg GD, Seppi K, van Eimeren T, Wenning GK, Boxer AL, Golbe LI, Litvan I (2017) Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord 32:853\u2013864","journal-title":"Mov Disord"},{"key":"2012_CR24","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1002\/mds.20497","volume":"20","author":"Y Huang","year":"2005","unstructured":"Huang Y, Garrick R, Cook R, O\u2019Sullivan D, Morris J, Halliday GM (2005) Pallidal stimulation reduces treatment-induced dyskinesias in \u201cminimal-change\u201d multiple system atrophy. Mov Disord 20:1042\u20131047","journal-title":"Mov Disord"},{"key":"2012_CR25","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1002\/mds.10246","volume":"17","author":"JM Kim","year":"2002","unstructured":"Kim JM, Lee KH, Choi YL, Choe GY, Jeon BS (2002) Levodopa-induced dyskinesia in an autopsy-proven case of progressive supranuclear palsy. Mov Disord 17:1089\u20131090","journal-title":"Mov Disord"},{"key":"2012_CR26","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1136\/jnnp-2017-315813","volume":"89","author":"S Koga","year":"2018","unstructured":"Koga S, Dickson DW (2018) Recent advances in neuropathology, biomarkers and therapeutic approach of multiple system atrophy. J Neurol Neurosurg Psychiatry 89:175\u2013184","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2012_CR27","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1001\/archneur.55.8.1099","volume":"55","author":"K Kompoliti","year":"1998","unstructured":"Kompoliti K, Goetz CG, Litvan I, Jellinger K, Verny M (1998) Pharmacological therapy in progressive supranuclear palsy. Arch Neurol 55:1099\u20131102","journal-title":"Arch Neurol"},{"key":"2012_CR28","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/nrneurol.2017.26","volume":"13","author":"F Krismer","year":"2017","unstructured":"Krismer F, Wenning GK (2017) Multiple system atrophy: insights into a rare and debilitating movement disorder. Nat Rev Neurol 13:232\u2013243","journal-title":"Nat Rev Neurol"},{"issue":"Suppl 12","key":"2012_CR29","doi-asserted-by":"publisher","first-page":"S83","DOI":"10.1002\/mds.20545","volume":"20","author":"AE Lang","year":"2005","unstructured":"Lang AE (2005) Treatment of progressive supranuclear palsy and corticobasal degeneration. Mov Disord 20(Suppl 12):S83\u2013S91","journal-title":"Mov Disord"},{"key":"2012_CR30","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0092-8674(02)00962-5","volume":"111","author":"FJ Lee","year":"2002","unstructured":"Lee FJ, Xue S, Pei L, Vukusic B, Ch\u00e9ry N, Wang Y, Wang YT, Niznik HB, Yu XM, Liu F (2002) Dual regulation of NMDA receptor functions by direct protein\u2013protein interactions with the dopamine D1 receptor. Cell 111:219\u2013230","journal-title":"Cell"},{"key":"2012_CR31","first-page":"61","volume":"113","author":"J Levin","year":"2016","unstructured":"Levin J, Kurz A, Arzberger T, Giese A, H\u00f6glinger GU (2016) The differential diagnosis and treatment of atypical Parkinsonism. Dtsch Arztebl Int 113:61\u201369","journal-title":"Dtsch Arztebl Int"},{"key":"2012_CR32","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.devcel.2015.02.002","volume":"32","author":"J Lim","year":"2015","unstructured":"Lim J, Yue Z (2015) Neuronal aggregates: formation, clearance, and spreading. Dev Cell 32:491\u2013501","journal-title":"Dev Cell"},{"key":"2012_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/WNL.47.1.1","volume":"47","author":"I Litvan","year":"1996","unstructured":"Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, Goetz CG, Golbe LI, Grafman J, Growdon JH, Hallett M, Jankovic J, Quinn NP, Tolosa E, Zee DS (1996) Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 47:1\u20139","journal-title":"Neurology"},{"key":"2012_CR34","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/mds.10459","volume":"18","author":"I Litvan","year":"2003","unstructured":"Litvan I, Bhatia KP, Burn DJ, Goetz CG, Lang AE, McKeith I, Quinn N, Sethi KD, Shults C, Wenning GK (2003) Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord 18:467\u2013486","journal-title":"Mov Disord"},{"key":"2012_CR35","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/S1474-4422(15)00058-7","volume":"14","author":"PA Low","year":"2015","unstructured":"Low PA, Reich SG, Jankovic J, Shults CW, Stern MB, Novak P, Tanner CM, Gilman S, Marshall FJ, Wooten F, Racette B, Chelimsky T, Singer W, Sletten DM, Sandroni P, Mandrekar J (2015) Natural history of multiple system atrophy in the USA: a prospective cohort study. Lancet Neurol 14:710\u2013719","journal-title":"Lancet Neurol"},{"issue":"Suppl 2","key":"2012_CR36","first-page":"S32","volume":"17","author":"CD Marsden","year":"1994","unstructured":"Marsden CD (1994) Problems with long-term levodopa therapy for Parkinson\u2019s disease. Clin Neuropharmacol 17(Suppl 2):S32\u2013S44","journal-title":"Clin Neuropharmacol"},{"key":"2012_CR37","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.parkreldis.2016.01.005","volume":"24","author":"WG Meissner","year":"2016","unstructured":"Meissner WG, Laurencin C, Tranchant C, Witjas T, Viallet F, Guehl D, Damier P, Houeto JL, Tison F, Eusebio A, Vital A, Streichenberger N, Lannes B, Maues de Paula A, Thobois S (2016) Outcome of deep brain stimulation in slowly progressive multiple system atrophy: a clinico-pathological series and review of the literature. Parkinsonism Relat Disord 24:69\u201375","journal-title":"Parkinsonism Relat Disord"},{"key":"2012_CR38","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/ana.410240304","volume":"24","author":"MM Mouradian","year":"1988","unstructured":"Mouradian MM, Juncos JL, Fabbrini G, Schlegel J, Bartko JJ, Chase TN (1988) Motor fluctuations in Parkinson\u2019s disease: central pathophysiological mechanisms, Part II. Ann Neurol 24:372\u2013378","journal-title":"Ann Neurol"},{"key":"2012_CR39","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s40478-017-0488-7","volume":"5","author":"A Mudher","year":"2017","unstructured":"Mudher A, Colin M, Dujardin S, Medina M, Dewachter I, Alavi Naini SM, Mandelkow EM, Mandelkow E, Buee L, Goedert M, Brion JP (2017) What is the evidence that tau pathology spreads through prion-like propagation? Acta Neuropathol Commun 5:99","journal-title":"Acta Neuropathol Commun"},{"key":"2012_CR40","doi-asserted-by":"publisher","first-page":"11406","DOI":"10.1523\/JNEUROSCI.1230-17.2017","volume":"37","author":"S Narasimhan","year":"2017","unstructured":"Narasimhan S, Guo JL, Changolkar L, Stieber A, McBride JD, Silva LV, He Z, Zhang B, Gathagan RJ, Trojanowski JQ, Lee VMY (2017) Pathological tau strains from human brains recapitulate the diversity of tauopathies in nontransgenic mouse brain. J Neurosci 37:11406\u201311423","journal-title":"J Neurosci"},{"key":"2012_CR41","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1097\/00002826-199308000-00006","volume":"16","author":"KA Nieforth","year":"1993","unstructured":"Nieforth KA, Golbe LI (1993) Retrospective study of drug response in 87 patients with progressive supranuclear palsy. Clin Neuropharmacol 16:338\u2013346","journal-title":"Clin Neuropharmacol"},{"key":"2012_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/mds.21060","volume":"22","author":"JG Nutt","year":"2007","unstructured":"Nutt JG (2007) Continuous dopaminergic stimulation: is it the answer to the motor complications of levodopa? Mov Disord 22:1\u20139","journal-title":"Mov Disord"},{"key":"2012_CR44","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1002\/mds.25364","volume":"28","author":"CW Olanow","year":"2013","unstructured":"Olanow CW, Kieburtz K, Rascol O, Poewe W, Schapira AH, Emre M, Nissinen H, Leinonen M, Stocchi F, Stalevo Reduction in Dyskinesia Evaluation in Parkinson\u2019s Disease (STRIDE-PD) Investigators (2013) Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson\u2019s disease. Mov Disord 28:1064\u20131071","journal-title":"Mov Disord"},{"key":"2012_CR45","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1474-4422(13)70293-X","volume":"13","author":"CW Olanow","year":"2014","unstructured":"Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, Vanagunas A, Othman AA, Widnell KL, Robieson WZ, Pritchett Y, Chatamra K, Benesh J, Lenz RA, Antonini A, LCIG Horizon Study Group (2014) Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson\u2019s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 13:141\u2013149","journal-title":"Lancet Neurol"},{"issue":"Pt 5","key":"2012_CR46","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1093\/brain\/awn065","volume":"131","author":"SS O\u2019Sullivan","year":"2008","unstructured":"O\u2019Sullivan SS, Massey LA, Williams DR, Silveira-Moriyama L, Kempster PA, Holton JL, Revesz T, Lees AJ (2008) Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. Brain 131(Pt 5):1362\u20131372","journal-title":"Brain"},{"key":"2012_CR47","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/ana.410390505","volume":"39","author":"SM Papa","year":"1996","unstructured":"Papa SM, Chase TN (1996) Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Ann Neurol 39:574\u2013578","journal-title":"Ann Neurol"},{"key":"2012_CR48","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1172\/JCI71640","volume":"124","author":"M Politis","year":"2014","unstructured":"Politis M, Wu K, Loane C, Brooks DJ, Kiferle L, Turkheimer FE, Bain P, Molloy S, Piccini P (2014) Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson\u2019s disease patients. J Clin Invest 124:1340\u20131349","journal-title":"J Clin Invest"},{"key":"2012_CR49","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/00002826-200111000-00002","volume":"24","author":"O Rascol","year":"2001","unstructured":"Rascol O, Fabre N (2001) Dyskinesia: l-dopa-induced and tardive dyskinesia. Clin Neuropharmacol 24:313\u2013323","journal-title":"Clin Neuropharmacol"},{"issue":"Suppl 1","key":"2012_CR50","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.1016\/j.parkreldis.2015.09.041","volume":"22","author":"G Respondek","year":"2016","unstructured":"Respondek G, Hoglinger GU (2016) The phenotypic spectrum of progressive supranuclear palsy. Parkinsonism Relat Disord 22(Suppl 1):S34\u2013S36","journal-title":"Parkinsonism Relat Disord"},{"key":"2012_CR51","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/WCO.0000000000000581","volume":"31","author":"G Respondek","year":"2018","unstructured":"Respondek G, Levin J, H\u00f6glinger GU (2018) Progressive supranuclear palsy and multiple system atrophy: clinicopathological concepts and therapeutic challenges. Curr Opin Neurol 31:448\u2013454","journal-title":"Curr Opin Neurol"},{"key":"2012_CR52","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3389\/fneur.2017.00037","volume":"8","author":"CD Rietdijk","year":"2017","unstructured":"Rietdijk CD, Perez-Pardo P, Garssen J, van Wezel RJ, Kraneveld AD (2017) Exploring Braak\u2019s hypothesis of Parkinson\u2019s disease. Front Neurol 8:37","journal-title":"Front Neurol"},{"key":"2012_CR53","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/S0149-7634(99)00069-X","volume":"24","author":"PS Sachdev","year":"2000","unstructured":"Sachdev PS, Br\u00fcne M (2000) Animal models of acute drug-induced akathisia\u2014a review. Neurosci Biobehav Rev 24:269\u2013277","journal-title":"Neurosci Biobehav Rev"},{"key":"2012_CR54","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1139\/y02-002","volume":"80","author":"V Sanci","year":"2002","unstructured":"Sanci V, Houle S, DaSilva JN (2002) No change in dopamine D1 receptor in vivo binding in rats after sub-chronic haloperidol treatment. Can J Physiol Pharmacol 80:36\u201341","journal-title":"Can J Physiol Pharmacol"},{"key":"2012_CR55","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1126\/science.1070532","volume":"296","author":"A Sawa","year":"2002","unstructured":"Sawa A, Snyder SH (2002) Schizophrenia: diverse approaches to a complex disease. Science 296:692\u2013695","journal-title":"Science"},{"key":"2012_CR56","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S0736-5748(00)00033-2","volume":"18","author":"A Sidhu","year":"2000","unstructured":"Sidhu A, Niznik HB (2000) Coupling of dopamine receptor subtypes to multiple and diverse G proteins. Int J Dev Neurosci 18:669\u2013677","journal-title":"Int J Dev Neurosci"},{"key":"2012_CR57","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/ana.22060","volume":"68","author":"F Stocchi","year":"2010","unstructured":"Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, Barone P, Lang AE, Olanow CW (2010) Initiating levodopa\/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 68:18\u201327","journal-title":"Ann Neurol"},{"key":"2012_CR58","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1212\/01.wnl.0000206363.57955.1b","volume":"66","author":"O Suchowersky","year":"2006","unstructured":"Suchowersky O, Gronseth G, Perlmutter J, Reich S, Zesiewicz T, Weiner WJ (2006) Practice Parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66:976\u2013982","journal-title":"Neurology"},{"key":"2012_CR59","doi-asserted-by":"publisher","first-page":"6445","DOI":"10.1523\/JNEUROSCI.1128-16.2016","volume":"36","author":"NC Swann","year":"2016","unstructured":"Swann NC, de Hemptinne C, Miocinovic S, Qasim S, Wang SS, Ziman N, Ostrem JL, San Luciano M, Galifianakis NB, Starr PA (2016) Gamma oscillations in the hyperkinetic state detected with chronic human brain recordings in Parkinson\u2019s disease. J Neurosci 36:6445\u20136458","journal-title":"J Neurosci"},{"key":"2012_CR60","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/j.1365-2990.2007.00907.x","volume":"33","author":"JQ Trojanowski","year":"2007","unstructured":"Trojanowski JQ, Revesz T, Neuropathology Working Group on MSA (2007) Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy. Neuropathol Appl Neurobiol 33:615\u2013620","journal-title":"Neuropathol Appl Neurobiol"},{"key":"2012_CR61","doi-asserted-by":"publisher","first-page":"e0172145","DOI":"10.1371\/journal.pone.0172145","volume":"12","author":"R Vasta","year":"2017","unstructured":"Vasta R, Nicoletti A, Mostile G, Dibilio V, Sciacca G, Contrafatto D, Cicero CE, Raciti L, Luca A, Zappia M (2017) Side effects induced by the acute levodopa challenge in Parkinson\u2019s disease and atypical parkinsonisms. PLoS One 12:e0172145","journal-title":"PLoS One"},{"key":"2012_CR62","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1212\/WNL.50.5.1323","volume":"50","author":"L Verhagen Metman","year":"1998","unstructured":"Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN (1998) Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson\u2019s disease. Neurology 50:1323\u20131326","journal-title":"Neurology"},{"issue":"4 Suppl 1","key":"2012_CR63","first-page":"S131","volume":"47","author":"JL Vitek","year":"2000","unstructured":"Vitek JL, Giroux M (2000) Physiology of hypokinetic and hyperkinetic movement disorders: model for dyskinesia. Ann Neurol 47(4 Suppl 1):S131\u2013S140","journal-title":"Ann Neurol"},{"key":"2012_CR64","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/S1474-4422(12)70327-7","volume":"12","author":"GK Wenning","year":"2013","unstructured":"Wenning GK, Geser F, Krismer F, Seppi K, Duerr S, Boesch S, K\u00f6llensperger M, Goebel G, Pfeiffer KP, Barone P, Pellecchia MT, Quinn NP, Koukouni V, Fowler CJ, Schrag A, Mathias CJ, Giladi N, Gurevich T, Dupont E, Ostergaard K, Nilsson CF, Widner H, Oertel W, Eggert KM, Albanese A, del Sorbo F, Tolosa E, Cardozo A, Deuschl G, Hellriegel H, Klockgether T, Dodel R, Sampaio C, Coelho M, Djaldetti R, Melamed E, Gasser T, Kamm C, Meco G, Colosimo C, Rascol O, Meissner WG, Tison F, Poewe W, European Multiple System Atrophy Study Group (2013) The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol 12:264\u2013274","journal-title":"Lancet Neurol"},{"key":"2012_CR65","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/ana.25132","volume":"83","author":"G Wenning","year":"2018","unstructured":"Wenning G, Trojanowski JQ, Kaufmann H, Wisniewski T, Rocca WA, Low PA (2018) Is multiple system atrophy an infectious disease? Ann Neurol 83:10\u201312","journal-title":"Ann Neurol"},{"key":"2012_CR66","first-page":"1189","volume":"19","author":"DR Williams","year":"2013","unstructured":"Williams DR, Litvan I (2013) Parkinsonian syndromes. Continuum (Minneap Minn) 19:1189\u20131212","journal-title":"Continuum (Minneap Minn)"},{"key":"2012_CR67","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1093\/brain\/awh488","volume":"128","author":"DR Williams","year":"2005","unstructured":"Williams DR, de Silva R, Paviour DC, Pittman A, Watt HC, Kilford L, Holton JL, Revesz T, Lees AJ (2005) Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson\u2019s syndrome and PSP-Parkinsonism. Brain 128:1247\u20131258","journal-title":"Brain"},{"key":"2012_CR68","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/s41598-018-37545-z","volume":"9","author":"X Zhang","year":"2019","unstructured":"Zhang X, Chou J, Liang J, Xiao C, Zhao Y, Sarva H, Henchcliffe C, Wang F (2019) Data-driven subtyping of Parkinson\u2019s disease using longitudinal clinical records: a cohort study. Sci Rep 9:797","journal-title":"Sci Rep"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-019-02012-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00702-019-02012-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-019-02012-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T23:22:16Z","timestamp":1589239336000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-019-02012-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,13]]},"references-count":66,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["2012"],"URL":"https:\/\/doi.org\/10.1007\/s00702-019-02012-0","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,13]]},"assertion":[{"value":"12 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}